157 related articles for article (PubMed ID: 28675057)
1. Multiple receptors shape the estrogen response pathway and are critical considerations for the future of in vitro-based risk assessment efforts.
Miller MM; McMullen PD; Andersen ME; Clewell RA
Crit Rev Toxicol; 2017 Aug; 47(7):564-580. PubMed ID: 28675057
[TBL] [Abstract][Full Text] [Related]
2. Alternatives to in vivo tests to detect endocrine disrupting chemicals (EDCs) in fish and amphibians--screening for estrogen, androgen and thyroid hormone disruption.
Scholz S; Renner P; Belanger SE; Busquet F; Davi R; Demeneix BA; Denny JS; Léonard M; McMaster ME; Villeneuve DL; Embry MR
Crit Rev Toxicol; 2013 Jan; 43(1):45-72. PubMed ID: 23190036
[TBL] [Abstract][Full Text] [Related]
3. An exposure:activity profiling method for interpreting high-throughput screening data for estrogenic activity--proof of concept.
Becker RA; Friedman KP; Simon TW; Marty MS; Patlewicz G; Rowlands JC
Regul Toxicol Pharmacol; 2015 Apr; 71(3):398-408. PubMed ID: 25656492
[TBL] [Abstract][Full Text] [Related]
4. Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.
Browne P; Noyes PD; Casey WM; Dix DJ
Environ Health Perspect; 2017 Sep; 125(9):096001. PubMed ID: 28934726
[TBL] [Abstract][Full Text] [Related]
5. On selecting a minimal set of in vitro assays to reliably determine estrogen agonist activity.
Judson RS; Houck KA; Watt ED; Thomas RS
Regul Toxicol Pharmacol; 2017 Dec; 91():39-49. PubMed ID: 28993267
[TBL] [Abstract][Full Text] [Related]
6. The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay.
Beames T; Moreau M; Roberts LA; Mansouri K; Haider S; Smeltz M; Nicolas CI; Doheny D; Phillips MB; Yoon M; Becker RA; McMullen PD; Andersen ME; Clewell RA; Hartman JK
Toxicol Appl Pharmacol; 2020 Jan; 387():114774. PubMed ID: 31783037
[TBL] [Abstract][Full Text] [Related]
7. Estrogenic endocrine disruptors: Molecular mechanisms of action.
Kiyama R; Wada-Kiyama Y
Environ Int; 2015 Oct; 83():11-40. PubMed ID: 26073844
[TBL] [Abstract][Full Text] [Related]
8. Editor's Highlight: Development of an In vitro Assay Measuring Uterine-Specific Estrogenic Responses for Use in Chemical Safety Assessment.
Miller MM; Alyea RA; LeSommer C; Doheny DL; Rowley SM; Childs KM; Balbuena P; Ross SM; Dong J; Sun B; Andersen MA; Clewell RA
Toxicol Sci; 2016 Nov; 154(1):162-173. PubMed ID: 27503385
[TBL] [Abstract][Full Text] [Related]
9. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
[TBL] [Abstract][Full Text] [Related]
10. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
11. Selective activation of zebrafish estrogen receptor subtypes by chemicals by using stable reporter gene assay developed in a zebrafish liver cell line.
Cosnefroy A; Brion F; Maillot-Maréchal E; Porcher JM; Pakdel F; Balaguer P; Aït-Aïssa S
Toxicol Sci; 2012 Feb; 125(2):439-49. PubMed ID: 22045033
[TBL] [Abstract][Full Text] [Related]
12. Current limitations and recommendations to improve testing for the environmental assessment of endocrine active substances.
Coady KK; Biever RC; Denslow ND; Gross M; Guiney PD; Holbech H; Karouna-Renier NK; Katsiadaki I; Krueger H; Levine SL; Maack G; Williams M; Wolf JC; Ankley GT
Integr Environ Assess Manag; 2017 Mar; 13(2):302-316. PubMed ID: 27791330
[TBL] [Abstract][Full Text] [Related]
13. The estrogenic activity of resveratrol: a comprehensive review of
Qasem RJ
Crit Rev Toxicol; 2020 May; 50(5):439-462. PubMed ID: 32744480
[No Abstract] [Full Text] [Related]
14. Vitellogenin synthesis in primary cultures of fish liver cells as endpoint for in vitro screening of the (anti)estrogenic activity of chemical substances.
Navas JM; Segner H
Aquat Toxicol; 2006 Oct; 80(1):1-22. PubMed ID: 16950525
[TBL] [Abstract][Full Text] [Related]
15. Comparative endpoint sensitivity of in vitro estrogen agonist assays.
Dreier DA; Connors KA; Brooks BW
Regul Toxicol Pharmacol; 2015 Jul; 72(2):185-93. PubMed ID: 25896097
[TBL] [Abstract][Full Text] [Related]
16. Evaluation and QSAR modeling on multiple endpoints of estrogen activity based on different bioassays.
Liu H; Papa E; Gramatica P
Chemosphere; 2008 Feb; 70(10):1889-97. PubMed ID: 17884132
[TBL] [Abstract][Full Text] [Related]
17. Agrochemicals with estrogenic endocrine disrupting properties: Lessons Learned?
Vandenberg LN; Najmi A; Mogus JP
Mol Cell Endocrinol; 2020 Dec; 518():110860. PubMed ID: 32407980
[TBL] [Abstract][Full Text] [Related]
18. In vitro-to-in vivo extrapolation (IVIVE) by PBTK modeling for animal-free risk assessment approaches of potential endocrine-disrupting compounds.
Fabian E; Gomes C; Birk B; Williford T; Hernandez TR; Haase C; Zbranek R; van Ravenzwaay B; Landsiedel R
Arch Toxicol; 2019 Feb; 93(2):401-416. PubMed ID: 30552464
[TBL] [Abstract][Full Text] [Related]
19. Chlorpyrifos: weight of evidence evaluation of potential interaction with the estrogen, androgen, or thyroid pathways.
Juberg DR; Gehen SC; Coady KK; LeBaron MJ; Kramer VJ; Lu H; Marty MS
Regul Toxicol Pharmacol; 2013 Aug; 66(3):249-63. PubMed ID: 23524272
[TBL] [Abstract][Full Text] [Related]
20. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
Pickford DB
Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
